Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score 11.53
- Piotroski Score 4.00
- Grade Buy
- Symbol (KYMR)
- Company Kymera Therapeutics, Inc.
- Price $44.94
- Changes Percentage (3.29%)
- Change $1.43
- Day Low $43.28
- Day High $45.94
- Year High $53.27
Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis, macrophage activation syndrome, general pustular psoriasis, and rheumatoid arthritis; IRAKIMiD program to treat MYD88-mutated diffuse large B cell lymphoma; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 02/20/2025
- Fiscal Year End N/A
- Average Stock Price Target $54.00
- High Stock Price Target $80.00
- Low Stock Price Target $31.00
- Potential Upside/Downside N/A
- Consensus Rating Strong Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$2.51
- Trailing P/E Ratio -13.13
- Forward P/E Ratio -13.13
- P/E Growth -13.13
- Net Income $-146,962,000
Income Statement
Quarterly
Annual
Latest News of KYMR
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
We're Not Worried About Kymera Therapeutics' (NASDAQ:KYMR) Cash Burn
Investors often find unprofitable companies appealing due to growth potential, like Salesforce.com's success. However, such companies carry risks of cash depletion. Analyzing Kymera Therapeutics' cash...
By Yahoo! Finance | 3 months ago -
Kymera Therapeutics, Inc. (KYMR) Stock Price, News, Quote & History - Yahoo Finance
Kymera Therapeutics, Inc. is a biopharmaceutical company specializing in developing small molecule therapeutics that target disease-causing proteins by utilizing the body's natural protein degradation...
By Yahoo! Finance | 4 months ago
